Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
EWTX 
Edgewise Therapeutics Inc (EWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: EWTX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $38.17
1 Year Target Price $38.17
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 63.32% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.61B USD | Price to earnings Ratio - | 1Y Target Price 38.17 |
Price to earnings Ratio - | 1Y Target Price 38.17 | ||
Volume (30-day avg) 10 | Beta 0.27 | 52 Weeks Range 10.60 - 30.48 | Updated Date 01/8/2026 |
52 Weeks Range 10.60 - 30.48 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.66% | Return on Equity (TTM) -30.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2052615266 | Price to Sales(TTM) - |
Enterprise Value 2052615266 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.6 | Shares Outstanding 105868434 | Shares Floating 60491106 |
Shares Outstanding 105868434 | Shares Floating 60491106 | ||
Percent Insiders 0.45 | Percent Institutions 107.15 |
Upturn AI SWOT
Edgewise Therapeutics Inc
Company Overview
History and Background
Edgewise Therapeutics Inc. was founded in 2017 by a team of experienced drug developers with a focus on creating novel therapies for underserved diseases. The company has rapidly advanced its pipeline, achieving significant preclinical milestones and initiating clinical trials for its lead candidates.
Core Business Areas
- Precision Medicine for Muscle Diseases: Edgewise Therapeutics is dedicated to developing small molecule drugs targeting the root causes of genetic muscle diseases. Their approach focuses on modulating specific protein interactions to restore cellular function.
Leadership and Structure
Edgewise Therapeutics is led by a management team with extensive experience in drug discovery, development, and commercialization. The company operates with a lean, research-intensive structure, focusing on advancing its pipeline through clinical stages.
Top Products and Market Share
Key Offerings
- EDG-5506: A first-in-class small molecule drug designed to treat Duchenne Muscular Dystrophy (DMD) and other dystroglycanopathies. EDG-5506 aims to reduce muscle damage and inflammation. Competitors in the DMD space include Sarepta Therapeutics (SRP-9001) and Pfizer (dadvorafen).
Market Dynamics
Industry Overview
The rare disease therapeutics market, particularly for genetic muscle disorders, is characterized by high unmet medical need, significant research investment, and a focus on precision medicine. The market is growing due to advancements in genetic understanding and therapeutic modalities.
Positioning
Edgewise Therapeutics is positioned as an innovator in precision medicine for rare genetic muscle diseases. Their key differentiator lies in their novel mechanism of action targeting the underlying pathology of these conditions, aiming to provide disease-modifying treatments.
Total Addressable Market (TAM)
The TAM for Duchenne Muscular Dystrophy alone is estimated to be in the billions of dollars globally. Edgewise Therapeutics is positioned to capture a significant portion of this market with its potentially disease-modifying therapy, provided successful clinical outcomes and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with a differentiated mechanism of action.
- Experienced leadership team with a track record in drug development.
- Focus on a high unmet medical need area (rare genetic muscle diseases).
- Strong preclinical data supporting lead candidates.
Weaknesses
- Early-stage company with limited revenue history.
- Reliance on successful clinical trial outcomes for future growth.
- High cost and complexity of drug development.
- Potential for manufacturing challenges at scale.
Opportunities
- Expanding pipeline to address other rare genetic muscle disorders.
- Partnerships and collaborations with larger pharmaceutical companies.
- Advancements in genetic diagnostics and patient identification.
- Growing investment in the rare disease space.
Threats
- Clinical trial failures or delays.
- Competition from other companies developing similar therapies.
- Regulatory hurdles and stringent approval processes.
- Reimbursement challenges for high-cost novel therapies.
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- Pfizer Inc. (PFE)
Competitive Landscape
Edgewise Therapeutics faces competition from established companies like Sarepta Therapeutics and Pfizer, which have existing therapies and extensive clinical development programs in DMD. Edgewise's advantage lies in its novel mechanism that aims to address a broader spectrum of muscle damage compared to some existing gene therapies.
Growth Trajectory and Initiatives
Historical Growth: Edgewise Therapeutics has experienced rapid growth in its pipeline development and team expansion since its inception. Its growth trajectory is marked by successful preclinical studies and the initiation of clinical trials.
Future Projections: Future growth projections are heavily dependent on the successful progression of its clinical candidates through Phase 1, Phase 2, and Phase 3 trials, leading to potential regulatory approval and commercialization. Analyst estimates would reflect these milestones.
Recent Initiatives: Key recent initiatives include advancing EDG-5506 into clinical trials, expanding its discovery platform, and securing financing to support ongoing development.
Summary
Edgewise Therapeutics Inc. is a promising early-stage biotechnology company focused on developing novel therapies for rare genetic muscle diseases. Its lead candidate, EDG-5506, shows potential for significant impact. While the company possesses strong scientific backing and a clear unmet medical need focus, it faces the inherent risks of clinical development, intense competition, and the need for substantial future funding. Success hinges on positive clinical trial outcomes and effective regulatory navigation.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., S-1, 10-K, 10-Q)
- Biotechnology Industry Reports
- Clinical Trial Databases (e.g., ClinicalTrials.gov)
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data for early-stage biotechnology companies can be highly volatile and is subject to change. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edgewise Therapeutics Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2021-03-26 | President, CEO & Director Dr. Kevin Koch Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://edgewisetx.com |
Full time employees 136 | Website https://edgewisetx.com | ||
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.